GNBT - Joe Moscato we believe in you - Tomo SETTE

avion65

Nuovo Utente
Registrato
3/8/10
Messaggi
2.551
Punti reazioni
74
A quella cifra faccio un busto in bronzo di kyro e lo metto in salone. :D
 

kyro

Nuovo Utente
Registrato
17/2/04
Messaggi
1.974
Punti reazioni
99
Mi sa che non ce la facciamo....:'(:'(:'(:'(

La cc è stata rimandata ai primi di gennaio quindi anche la news dell'accordo (sempre se c'è).
Entro l'anno potrebbero però comunicare i dati finali della fase III oral-lyn... tanto per dare un'altra spintarella al titolo.

La fine del tunnel OTC è vicina. Al nasdaq Antigen attrarrà capitali e GNBT all'AMEX verrà vista come una nuova società. OK!
 

Gianfe1

Nuovo Utente
Registrato
15/1/09
Messaggi
1.674
Punti reazioni
29
0.173 - 1.96 M
sbaglio o è un gran bel risultato in questo nostro contesto?
 

CrazyStock

Nuovo Utente
Registrato
13/6/09
Messaggi
556
Punti reazioni
20
Form 8-K for GENEREX BIOTECHNOLOGY CORP

23-Dec-2011

Other Events


Item 8.01. Other Events.

During the period July 1 through November 30, 2011 Generex Biotechnology Corporation (the" Company") issued, pursuant to a contractual commitment, 750,000 shares of common stock, in the aggregate, to a consultant for services rendered. The shares issued were valued at $0.09 to $0.13 per share based on the quoted market price of the Company's common stock on the designated dates of the issuances. All of the shares were issued without registration and, thereofore, were subject to restrictions on transfer. To avoid the consequences of the issuance of such shares at low attributed prices, the consultant has agreed to return the shares for cancellation on the following terms. The Company will issue to the consultant a promissory note in the principal amount of $116,250, due December 31, 2012, with interest payable at 10% per annum. The consultant, at its option, may convert the principal and accrued interest into the Company's common stock at a conversion price equal to 85% of the current market price of the shares, provided that the note may not be converted into shares at a price lower than $.15 per share.
Summary of GENEREX BIOTECHNOLOGY CORP - Yahoo! Finance
 

Gianfe1

Nuovo Utente
Registrato
15/1/09
Messaggi
1.674
Punti reazioni
29
Form 8-K for GENEREX BIOTECHNOLOGY CORP

23-Dec-2011

Other Events


Item 8.01. Other Events.

During the period July 1 through November 30, 2011 Generex Biotechnology Corporation (the" Company") issued, pursuant to a contractual commitment, 750,000 shares of common stock, in the aggregate, to a consultant for services rendered. The shares issued were valued at $0.09 to $0.13 per share based on the quoted market price of the Company's common stock on the designated dates of the issuances. All of the shares were issued without registration and, thereofore, were subject to restrictions on transfer. To avoid the consequences of the issuance of such shares at low attributed prices, the consultant has agreed to return the shares for cancellation on the following terms. The Company will issue to the consultant a promissory note in the principal amount of $116,250, due December 31, 2012, with interest payable at 10% per annum. The consultant, at its option, may convert the principal and accrued interest into the Company's common stock at a conversion price equal to 85% of the current market price of the shares, provided that the note may not be converted into shares at a price lower than $.15 per share.
Summary of GENEREX BIOTECHNOLOGY CORP - Yahoo! Finance

mi sembra positivo, o no? :mmmm:
 

ilpensionato

I have no dreams
Registrato
11/12/09
Messaggi
11.578
Punti reazioni
210
0.173 - 1.96 M
sbaglio o è un gran bel risultato in questo nostro contesto?
si
step by step senza strappi, il mortirolo lo puoi fare solo cosi:D

Form 8-K for GENEREX BIOTECHNOLOGY CORP

23-Dec-2011

Other Events


Item 8.01. Other Events.

During the period July 1 through November 30, 2011 Generex Biotechnology Corporation (the" Company") issued, pursuant to a contractual commitment, 750,000 shares of common stock, in the aggregate, to a consultant for services rendered. The shares issued were valued at $0.09 to $0.13 per share based on the quoted market price of the Company's common stock on the designated dates of the issuances. All of the shares were issued without registration and, thereofore, were subject to restrictions on transfer. To avoid the consequences of the issuance of such shares at low attributed prices, the consultant has agreed to return the shares for cancellation on the following terms. The Company will issue to the consultant a promissory note in the principal amount of $116,250, due December 31, 2012, with interest payable at 10% per annum. The consultant, at its option, may convert the principal and accrued interest into the Company's common stock at a conversion price equal to 85% of the current market price of the shares, provided that the note may not be converted into shares at a price lower than $.15 per share.
Summary of GENEREX BIOTECHNOLOGY CORP - Yahoo! Finance
buona pure questa, anchs e non pesava molto, ma tutto fa brodoOK!
 

Gianfe1

Nuovo Utente
Registrato
15/1/09
Messaggi
1.674
Punti reazioni
29
Buon Natale e tutti! Ci risentiamo martedì!!! :bye:
 

ilnazareno

Hegesippe' Simon!
Registrato
26/12/08
Messaggi
5.649
Punti reazioni
115

Allegati

  • mnkd.JPG
    mnkd.JPG
    89 KB · Visite: 190

ewilly1

Nuovo Utente
Registrato
25/2/08
Messaggi
2.526
Punti reazioni
42
sotto i 10 in prossimità del triplo mini o rientro anche io